{"id":4455,"date":"2025-09-09T13:40:50","date_gmt":"2025-09-09T10:40:50","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4455"},"modified":"2025-09-09T13:43:30","modified_gmt":"2025-09-09T10:43:30","slug":"solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/","title":{"rendered":"Solid Biosciences lance un essai clinique de phase 3 sur la th\u00e9rapie g\u00e9nique SGT-003 (IMPACT DUCHENNE) chez les hommes ambulants"},"content":{"rendered":"

L'\u00e9tude de phase 3 (NCT07160634) de la th\u00e9rapie g\u00e9nique SGT-003 d\u00e9velopp\u00e9e par Solid Biosciences devrait d\u00e9buter en octobre 2025 et s'achever en janvier 2029.<\/strong> L'\u00e9tude de phase 3 SGT-003 inclura 80 hommes ambulatoires, de plus les lieux d'\u00e9tude n'ont pas encore \u00e9t\u00e9 communiqu\u00e9s. En savoir plus<\/strong>: Questions fr\u00e9quemment pos\u00e9es sur la th\u00e9rapie g\u00e9nique Solid Biosciences SGT-003<\/a><\/p>\n\n\n\n

\u00c9tude de phase 3 sur la th\u00e9rapie g\u00e9nique SGT-003 \u2013 NCT07160634 \u2013<\/h2>\n\n\n\n

Il s'agit d'une \u00e9tude de phase III, en double aveugle, contr\u00f4l\u00e9e par placebo, dont l'objectif principal \u00e9tait d'\u00e9valuer l'efficacit\u00e9 d'une perfusion intraveineuse unique de SGT-003 chez des patients p\u00e9diatriques ambulatoires de sexe masculin atteints de DMD. Les objectifs secondaires incluent l'\u00e9valuation d'autres crit\u00e8res d'efficacit\u00e9 et de s\u00e9curit\u00e9.<\/p>\n\n\n\n

D\u00e9but de l'\u00e9tude (estim\u00e9)<\/strong>: 2025-10<\/p>\n\n\n\n

Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2029-01<\/p>\n\n\n\n

Ach\u00e8vement de l'\u00e9tude (estim\u00e9)<\/strong>: 2034-01<\/p>\n\n\n\n

Nombre de participants (estim\u00e9)<\/strong>: 80<\/p>\n\n\n\n

Type d'\u00e9tude<\/strong>: Interventionnel<\/p>\n\n\n\n

Emplacements<\/strong>: Aucune donn\u00e9e de localisation pour le moment.<\/p>\n\n\n\n

\u00c2ges admissibles aux \u00e9tudes<\/strong>: 7 \u00e0 11 ans (hommes ambulants)<\/p>\n\n\n\n

Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013 NCT07160634<\/a> \u2013<\/p>\n\n\n\n

Comment participer \u00e0 l'essai clinique SGT-003<\/h2>\n\n\n\n

Pour participer \u00e0 l'essai clinique de phase 3 SGT-003, vous pouvez utiliser les coordonn\u00e9es ci-dessous.<\/p>\n\n\n\n

Nom<\/strong>: Solid Biosciences<\/p>\n\n\n\n

Num\u00e9ro de t\u00e9l\u00e9phone<\/strong>: 6173374680<\/p>\n\n\n\n

E-mail<\/strong>: clinicaltrials@solidbio.com<\/p>","protected":false},"excerpt":{"rendered":"

The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 […]<\/p>\n","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,61,419,110,170,109],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy","tag-impact-duchenne","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"subtitle":"Solid Biosciences a annonc\u00e9 qu'elle lancerait un essai clinique de phase 3 pour sa th\u00e9rapie g\u00e9nique prometteuse SGT-003 pour la dystrophie musculaire de Duchenne.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}